Loading data for KTTAW — first visit, this takes a few seconds.
Pasithea Therapeutics Corp. (KTTAW)
NasdaqCM: KTTAW
· Real-Time Price · USD
0.01
+0.01 (n/a)
At close: Sep 02, 2026, 3:29 PM
The price, the headline numbers and the latest news, in one place.
Pasithea Therapeutics Corp. (KTTAW) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.3M |
| 0.29 | |
| n/a | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.00 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0 |
| Volume | 10,700 |
| Avg. Volume (20D) | n/a |
| Open | 0.01 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.01 |
| 52-Week Range | 0.00 - 0.01 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KTTAW
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and B...
IPO Date Jul 17, 2026
Employees 5
Stock Exchange NasdaqCM
Ticker Symbol KTTAW
Website https://www.pasithea.com
Financial Performance
In 2025, Pasithea Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -20.43M, an increase of 46.91%.
Financial StatementsEarnings Surprise
Pasithea Therapeutics has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.